Cancer uses metabolic hormones (e.g., insulin, leptin) caused by overweight, diabetes, or pre-diabetes to promote cancer progression and metastases. Yet, the co-occurence of cancer and insulin that affects millions of cancer patients worldwide is overlooked as a major contributor to cancer progression. What’s worse, many anti-cancer treatments cause metabolic dysfunction which can limit drug effectiveness and even lead to treatment resistance.
SynDevRx – the leader in the emerging field of metabo-oncology – is tackling this urgent and unmet medical need with its clinical drug evexomostat (SDX-7320).